lx 3

LX-3 is a selective activator of the p38 mitogen-activated protein kinase (MAPK) pathway, which de-represses a subset of endogenous genes repressed by DNA methylation.

LX-2931(LX-3305) is a sphingosine-1-phosphate cleavage enzyme (S1P) inhibitor for the treatment of rheumatoid arthritis.

Pexidartinib (PLX-3397) is a capsule containing a small-molecule receptor tyrosine kinase (RTK) inhibitor targeting KIT, CSF1R, and FLT3, with potential antineoplastic activity.

BLX3887 is a highly potent and selective inhibitor of 15-lipoxygenase type 1 (15-LO-1), exhibiting an IC50 of 32 nM in cell-free enzyme assays, with marked selectivity over 15-LO-2, which it does not inhibit, as well as over 5-LO (IC50 = 472 nM) and 12-LO (IC50 = 3,310 nM). BLX3887 selectively suppresses 15-LO metabolite production in eosinophils over neutrophils at 10 μM while additionally inhibiting endocytosis and migration of human peripheral blood mononuclear cell–derived dendritic cells in vitro, highlighting its utility in inflammatory and immune cell signaling research.

Minzasolmin(DLX-313) is an alpha-synuclein misfolding inhibitor for the study of Parkinson's disease.

Pexidartinib hydrochloride (PLX-3397 HCl) is a selective, orally active, ATP-competitive CSF1R/M-CSFR inhibitor and c-Kit inhibitor with IC50 values of 20 and 10 nM, respectively, capable of inducing cancer cell apoptosis.

RLX-33 is a potent and selective antagonist of relaxin family peptide 3 (RXFP3) that crosses the blood-brain barrier and also blocks relaxin 3-induced ERK1/2 phosphorylation. RLX-33 can block the increase in food intake induced by the RXFP3 selective agonist R3/I5 in rats.RLX-33 can be used to study the metabolic syndrome.

GLX351322 is NADPH Oxidase 4 Inhibitor with IC50 of 5 μM.

PLX-3618 is an effective BRD4 molecular glue degrader (DC50=12.2 nM) that recruits the E3 ligase substrate receptor DCAF11, promoting BRD4 polyubiquitination and proteasomal degradation to induce apoptosis in AML cells.

BLX-301 is a humanized monoclonal antibody against CD20, exhibiting antitumor activity. It is applicable in studies related to diseases such as non-Hodgkin's lymphoma and rheumatoid arthritis.

Dual Galectin-3/EGFR-IN-1 (Compound 29) is a dual inhibitor targeting Galectin-3 and EGFR, with dissociation constants (KD) of 52.29 μM and 3.31 μM, respectively. It inhibits TGF-β-induced hepatic stellate cell (HSC) activation, induces apoptosis in LX-2 cells, and shows antifibrotic activity in the liver.

C18 dihydro Ceramide is a bioactive sphingolipid and precursor in the de novo synthesis of C18 ceramide that lacks the 4,5-trans double bond. [1] Increased C18 dihydroceramide lipid levels lead to increased triacylglycerol storage and autophagosome accumulation as well as upregulation of the fibrosis markers α-SMA and FGF2 in Chang and LX-2 liver cells. C18 dihydro Ceramide is elevated in the plasma of pre-diabetics up to 9 years prior to the onset of type 2 diabetes. [2] It is also elevated in the skin of patients with lesional atopic dermatitis.[3]

LX2343 is a BACE1 enzyme inhibitor with an IC50 value of 11.43±0.36 μM and acts as a non-ATP competitive PI3K inhibitor with an IC50 of 15.99±3.23 μM. Additionally, LX2343 stimulates autophagy, promoting Aβ clearance.

LX-039 is a potent, selective, orally active estrogen receptor degrader (EC50: 2.99 nM) with antitumor effects.LX-039 has indole C-3 chloride atoms.LX-039 has good pharmacokinetic properties in mice, low clearance, high blood levels and oral exposure.